SynthesisJournal of the American Heart Association2023
Outcomes of Percutaneous Coronary Intervention for In-Stent Restenosis Versus De Novo Lesions: A Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Intracoronary Imaging in Brachytherapy: Opportunity Knocks.JACC. Advances · 2026Article
- Recurrent In-Stent Restenosis Treated With a Novel Technique: The Double-DCB Technique.JACC. Case reports · 2026Article
- Determinants of In-Stent Restenosis in ST-Elevation Myocardial Infarction: Insights from a Single-Center Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Observational
- In-Stent Restenosis Pathophysiology and Risk Factors: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Comparison of Percutaneous Coronary Intervention Outcomes for in-Stent vs de Novo Chronic Total Occlusions: A Meta-Analysis.Therapeutics and clinical risk management · 2026Review
- Development and validation of an interpretable machine learning model for concurrent identification of kinesiophobia in older patients with coronary heart disease after percutaneous coronary intervention.Frontiers in medicine · 2026Article
- Diabetes-related ten-year outcomes after percutaneous coronary intervention of in-stent restenosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- Changes of Serum CTRP12 in Patients With Coronary Artery Disease After the Treatment of Percutaneous Coronary Intervention and Its Relationship With In-Stent Restenosis.Clinical cardiology · 2026Article
- The ApoB/ApoA-I ratio and the risk of in-stent restenosis following drug-eluting stent implantation in patients with coronary heart disease: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Remnant Cholesterol as a Predictor of Target-Vessel Failure in Patients With In-Stent Restenosis.Reviews in cardiovascular medicine · 2025Article
- In-Stent Restenosis: Incidence, Mechanisms, and Treatment Options.Current cardiology reports · 2025Review
- From Mechanisms to Management: Tackling In-Stent Restenosis in the Drug-Eluting Stent Era.Current cardiology reports · 2025Review
- Article
- Predictive value of combined MHR and Lp(a) for in-stent restenosis in coronary heart disease patients: a study based on GEE model.Frontiers in cardiovascular medicine · 2025Article
- Clinical Significance of Optical Coherence Tomography-Guided Percutaneous Coronary Intervention for In-Stent Restenosis Within Drug-Eluting Stents: Impact on Patient Outcomes.Journal of the American Heart Association · 2024Article
- Elucidating the Relationship between Neutrophil-Lymphocyte Ratio and Plaque Composition in Patients with Drug-Eluting Stent Restenosis by Virtual Histology-Intravascular Ultrasound.Journal of cardiovascular development and disease · 2024Article
- Drug-Eluting Balloons in Calcified Coronary Lesions: A Meta-Analysis of Clinical and Angiographic Outcomes.Journal of clinical medicine · 2024Article
- Current Management of In-Stent Restenosis.Journal of clinical medicine · 2024Review
- Intrastent Restenosis: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Therapeutic biomaterials with liver X receptor agonists based on the horizon of material biology to regulate atherosclerotic plaque regressionRegenerative biomaterials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In-stent restenosis (ISR) is commonly encountered even in the era of contemporary percutaneous coronary intervention (PCI). There is a paucity of data on the comparative outcomes of PCI for ISR lesions versus de novo lesions. Methods and Results An electronic search was conducted for MEDLINE, Cochrane, and Embase through August 2022 for studies comparing the clinical outcomes after PCI for ISR versus de novo lesions. The primary outcome was major adverse cardiac events. Data were pooled using a random-effects model. The final analysis included 12 studies, with a total of 708 391 patients, of whom 71 353 (10.3%) underwent PCI for ISR. The weighted follow-up duration was 29.1 months. Compared with de novo lesions, PCI for ISR was associated with a higher incidence of major adverse cardiac events (odds ratio [OR], 1.31 [95% CI, 1.18-1.46]). There was no difference on a subgroup analysis of chronic total occlusion lesions versus none (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.